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Abstract
Background and Purpose: Histotripsy is a nonthermal focused ultrasound technology that uses acoustic cavi-
tation to homogenize tissue. Previous research has demonstrated that the prostatic urethra is more resistant to
histotripsy effects than prostate parenchyma, a finding that may complicate the creation of transurethral re-
section of the prostate-like treatment cavities. The purpose of this study was to characterize the endoscopic
appearance of the prostatic urethra during and after histotripsy treatment and to identify features that are
predictive of urethral disintegration.
Materials and Methods: Thirty-five histotripsy treatments were delivered in a transverse plane traversing the
prostatic urethra in 17 canine subjects (1–3/prostate ‡ 1 cm apart). Real-time endoscopy was performed in the
first four subjects to characterize development of acute urethral treatment effect (UTE). Serial postprocedure
endoscopy was performed in all subjects to assess subsequent evolution of UTE.
Results: Endoscopy during histotripsy was feasible with observation of intraurethral cavitation, allowing
characterization of the real-time progression of UTE from normal to frank urethral disintegration. While acute
urethral fragmentation occurred in 3/35 (8.6%) treatments, frank urethral disintegration developed in 24/35
(68.5%) within 14 days of treatment. Treating until the appearance of hemostatic pale gray shaggy urothelium
was the best predictor of achieving urethral fragmentation within 14 days of treatment with positive and
negative predictive values of 0.91 and 0.89, respectively.
Conclusion: Endoscopic assessment of the urethra may be a useful adjunct to prostatic histotripsy to help guide therapy
to ensure urethral disintegration, allowing drainage of the homogenized adenoma and effective tissue debulking.
Introduction
Surgical therapy for benign prostatic hyperplasia(BPH) has consisted of endoscopic debulking of the
prostate for decades, with transurethral resection of the
prostate (TURP) being considered the gold standard. More
recently, laser-based therapies, including photovaporization
of the prostate and holmium laser enucleation of the prostate,
have emerged as promising alternative debulking therapies
with decreased morbidity compared with TURP.1,2 These
therapies, however, remain invasive with associated surgical
risks. As a result, less invasive technologies have been pur-
sued, including transurethral microwave thermotherapy and
transurethral needle ablation, which thermally coagulate BPH
tissue while sparing the urethra from damage.3 While these
approaches achieve therapeutic benefit, they have failed to
replicate the efficacy and durability of TURP.4,5 These defi-
ciencies combined with many men now presenting later in life
with greater comorbidities and greater risk of preoperative
complications and morbidity6 have created a need for the
development of less invasive treatment modalities that rep-
licate the tissue debulking achieved with TURP.
Histotripsy, an experimental noninvasive extracorporeal
focused ultrasound (US) technology, is capable of fractionat-
ing prostate tissue in an in vivo canine model with resultant
tissue debulking.7 Histotripsy involves delivery of high am-
plitude, short (4 ls) pulses of US energy to a cigar-shaped
geometric focal volume resulting in the development of mi-
crobubbles. The oscillation, coalescence, and collapse of these
bubbles produces mechanical fractionation of targeted tis-
sues, reducing tissue architecture and cellular structures to a
fine slurry of acellular debris. Volumetric ablation is accom-
plished by moving the transducer focal volume throughout
the targeted region. As the tissue is converted to homogenate,
the US appearance becomes progressively hypoechoic.8–11
Transabdominal histotripsy of the prostate is safe and
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effective in an in vivo canine BPH model,12 producing dose-
dependent tissue debulking of the adenomatous BPH tissue13
with minimal hematuria, even in an anticoagulated model.14
The strategy for the development of histotripsy therapy for
BPH is to produce a TURP-like defect. To achieve this goal, the
prostatic urethra as well as the adjacent parenchymal tissue
must be fractionated. Previous work has demonstrated the
prostatic urethra to be more resilient to histotripsy than
prostate parenchyma, necessitating a greater number of
acoustic pulses to achieve tissue disintegration.13 In addition,
unlike the progressive US changes seen with parenchymal
homogenization, prostatic urethral disintegration is difficult
to discern with real-time US imaging.
In this study, we sought to endoscopically visualize and
characterize the chronology of prostatic urethral tissue chan-
ges induced by histotripsy. Furthermore, we hypothesized
that characteristic endoscopic tissue features resulting from




After receiving approval from the university committee for
animal use and care, 18 intact male canine subjects weighing
25.0 to 33.6 kg were obtained. Subjects were anesthetized with
subcutaneous acepromazine (0.1 mg/kg) and intravenous
propofol (2-8 mg/kg) and intubated. They were prepped with
a tap water enema with digital rectal disimpaction after in-
tubation. The lower abdomen and suprapubic region were
shaved before positioning each subject supine on the proce-
dural table. Inhalational anesthesia (isoflurane 1%–2%) was
maintained throughout treatment. All subjects received in-
tramuscular penicillin G benzathine (40,000 IU/kg) before the
procedure and on postoperative (POD) days 3 and 7 for
prophylaxis. Carprofen (2.2 mg/kg/d) was administered or-
ally before the procedure and for 24 hours afterward for an-
algesia. Flexible endoscopy was performed with an 8.2F
flexible ureteroscope (DUR-8, Gyrus ACMI, Southborough,
MA) before histotripsy treatment to document a normal lower
urinary tract and to serve as an intrasubject control. No uri-
nary catheter was left in place after treatment.
Experimental setup and procedure
Transrectal US (TRUS) imaging was performed using a
Logiq 6 US scanner (GE Healthcare, Waukesha, WI) with a
model ERB probe positioned manually and fixed in a custom
holder. The prostate volume was estimated using the stepper
volume technique tracing the prostate perimeter on trans-
verse slices at 2.5 mm intervals. The therapeutic system con-
sisted of a 16-element piezoceramic composite array (750 kHz,
11 · 14-cm diameter oval shape, focal length 10 cm, focal vol-
ume 3 · 3 · 8 mm; Imasonic, Voray sur l’Ognon, France) on a
three-axis computer-controlled positioning system (MATLAB,
MathWorks, Natick, MA). Coupling was achieved by placing
the therapy transducer in a bath of degassed water contained in
a plastic membrane in direct contact with the shaved abdomen.
One subject received sham treatment, and 17 subjects re-
ceived histotripsy treatment. Histotripsy pulses consisted of
five cycle bursts of acoustic energy at 750 kHz, with a duty
cycle less than 1% and pulse repetition frequency ranging
from 50 to 2000 Hz. Each treatment consisted of delivery of
3000 to 100,000 histotripsy pulses per mm of the treatment
path on a single transverse plane that intersected the urethra
and periurethral tissues (Fig. 1). A total of one to three treat-
ments separated by at least 1 cm along the apex-base axis were
delivered per prostate, dependent on prostate length.
FIG. 1. Experimental setup with coupling bath of degassed water positioned over suprapubic region of supine canine
subject. The histotripsy transducer is suspended in the water bath and translated to create transverse treatment planes
transecting the prostatic urethra.
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Histotripsy treatment was performed in the first four sub-
jects with the flexible ureteroscope positioned in a retrograde
fashion just distal to the treatment zone on TRUS to minimize
effect on treatment, yet allow intraurethral visualization of the
cavitation cloud.
Postprocedure care and endoscopic evaluation
After completion of histotripsy treatment, cystoscopy was
performed to evaluate for acute changes in urethral appear-
ance. All subjects recovered from anesthesia and were moni-
tored for treatment-related adverse events. Cystoscopy was
repeated on PODs 1, 3, 7, and then weekly until euthanasia.
Repeated TRUS under anesthesia was repeated weekly until
euthanasia. Ten subjects were euthanized on POD14 as ini-
tially planned. Two subjects were euthanized early on POD 2
after development of intraperitoneal urinoma secondary to
full thickness prostatic urethra and parenchymal disintegra-
tion through the capsule. Four subjects with normal en-
doscopy despite TRUS evidence of homogenization of
parenchymal tissue adjacent to the prostatic urethra were
maintained to POD 21 to allow further chronologic assess-
ment of the urethra. Two subjects in which urethral disinte-
gration developed before POD 14 were maintained to POD 28
to assess the evolution of the treatment cavity.
At the time of euthanasia, TRUS imaging and retrograde
endoscopy (with flexible ureteroscope) were performed.
Next, a suprapubic incision was made and a cystotomy
created through which antegrade cystourethroscopy was
performed using a 16F flexible cystoscope (Cy2, Olympus).
The prostate, bladder, and adjacent rectum were then sur-
gically removed en bloc. The prostate, bladder, and rectal
tissues were inspected grossly for injury. Harvested pros-
tates were fixed in formalin for 1 week, cut into 5-mm thick
slabs, dehydrated in 25% ethanol, paraffin embedded, cut
using a microtome in 5-lm sections at 1-mm increments,
mounted, and stained with hematoxylin and eosin for his-
tologic assessment.
FIG. 2. Endoscopic appearance of urethra at *0.5 s intervals with bubble cloud (at tip of arrow) in urethral lumen (A).
Transrectal ultrasound appearance of histotripsy bubble cloud in urethral wall and lumen during treatment (B).
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Statistical analysis
The reliability of postprocedure endoscopic findings on
POD–0 to predict the development of macroscopic urethral
fragmentation/disintegration was evaluated using sensitiv-
ity, specificity, and positive (PPV) and negative (NPV) pre-
dictive value.
Results
A total of 35 prostate histotripsy treatments (1-3 treatments
per prostate, dependent on prostate size) were applied to 17
canine subjects, and a sham procedure was performed on 1
subject. Mean prostate volume was 20.7 – 5.2 cc. During the
course of histotripsy treatment, the cavitation bubble cloud
was easily seen with TRUS, and targeted parenchymal tissue
became progressively hypoechoic while the urethra appeared
structurally intact on US images.
Flexible endoscopy performed during histotripsy therapy
in the first four subjects (six treatments) provided direct in-
traluminal visualization of the cavitation bubble cloud as it
traversed the urethral lumen (Fig. 2) (supplementary videos
demonstrating the technique are available at www.liebert
online.com.end) and revealed a dose-dependent progression
of treatment effect. Visualized urethral treatment effect began
with as few as 2000 to 3000 pulses/mm of treatment path,
producing petechial hemorrhage and active bleeding (Fig. 3).
These findings evolved to relative hemostasis and the ap-
pearance of pale, shaggy, shedding urothelium with further
treatment in as little as 5000 to 10,000 pulses/mm in the most
susceptible subject. With continued treatment, small flaps of
urethral tissue formed that coalesced before frank urethral
disintegration.
Endoscopy immediately after histotripsy (POD 0) revealed
normal appearing urethra between targeted transverse treat-
ment planes in subjects undergoing more than one treatment
per prostate, demonstrating tight confinement of treatment
effect. While gross urethral disintegration was apparent in 3/
35 (8.6%) treatment zones on POD 0 endoscopy, it developed
in 24/35 (68.5%) by POD 14. POD 0 and subsequent endo-
scopic appearance of the prostatic urethra did not differ be-
tween the four subjects undergoing endoscopy during active
treatment and those that did not. In subjects maintained to
POD 21, no additional urethral disintegration was observed
after POD 14.
Transverse treatment planes without endoscopically ob-
served urethral disintegration by POD 14 were found on TRUS
to have persistent internal echoes and/or a gravity fluid/
debris line within the adjacent targeted parenchyma, while
planes with cavities communicating with the urethra had ab-
sent or minimal internal echoes consistent with drainage of the
homogenized material via the urethra. These findings were
confirmed histologically (Fig. 4). The sham subject’s urethra
FIG. 3. Real-time endoscopic surveillance of histotripsy treatment showing normal pretreatment urethra and prostate
histotripsy treatment effect at 2000, 5000, 15,000, and 25,000 pulses/mm of treatment path in the same subject. Note the
development of petechial hemorrhage (2000 pulses/mm) followed by hemostasis and the appearance of shaggy gray ur-
othelium (5000 pulses/mm) and subsequently a small flap of tissue (15,000 pulses/mm). (The urethra has rotated slightly
from pretreatment to treatment secondary to compression from extracorporeal water.)
FIG. 4. Endoscopic appearance of the prostatic urethra immediately after histotripsy treatment, demonstrating grade 1 (*)
and grade 2 (arrowhead) treatment effect (A), and on postoperative day 14 demonstrating urethral disintegration (B), with
confirmatory histologic findings (C) in the same subject.
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and prostate remained normal throughout the postprocedure
period on serial endoscopy and TRUS, respectively.
Using the real-time endoscopy data, a grading scale
(0 = normal, 1 = active bleeding and/or petechial hemorrhage,
2 = urothelial shedding, 3 = urothelial flap, 4 = urethral wall
necrosis, 5 = frank urethral disintegration/perforation) was
constructed (Fig. 5) to characterize the endoscopically appar-
ent degree of urethral treatment effect. Immediate POD 0 en-
doscopy was interpretable in all cases except for two subjects
(accounting for four treatment zones) in which equipment
damage prevented adequate visualization; these subjects were
excluded from the analysis. Of the 31 endoscopically evaluable
treatment planes, POD 0 endoscopy revealed ‡ grade 1 treat-
ment effect in 28/31, ‡ grade 2 effect in 22/31, and ‡ grade 3
effect in 9/31. Presence of at least grade 1 treatment effect had
PPV and NPV of 0.75 and 1.00, respectively, for subsequent
development of urethral disintegration by POD 14 (Table 1).
Presence of at least grade 2 treatment effect was associated
with a PPV and NPV of 0.91 and 0.89, while grade 3 or greater
treatment effect had PPV and NPV of 1.00 and 0.45 for de-
velopment of subsequent urethral fragmentation. Achieving
grade 3 damage on POD 0 endoscopy was associated with the
development of gross urethral disintegration within 24 hours
on follow-up endoscopy in 8/9 (88.9%) subjects.
In three subjects with very small prostates (mean 19.9 cc),
rectoprostatic fistulae occurred but were managed conserva-
tively. Urinary retention developed in one additional subject
on POD 2 that was managed with an indwelling urinary
catheter for 48 hours; the subject subsequently did well.
Discussion
In the present study, we characterized the dose-dependent
endoscopic appearance and chronologic progression of
FIG. 5. Endoscopic grading scale of prostatic urethral histotripsy treatment effect. (A) Appearance of normal untreated
urethra. (B) Appearance of grade 1 damage (active bleeding – petechial hemorrhage), (C) grade 2 damage (shedding
urothelium), (D) grade 3 damage (urothelial flap), (E) grade 4 damage (urethral wall necrosis), (F) grade 5 (frank urethral
disintegration/perforation). TL = true lumen.
Table 1. Endoscopic Assessment of Urethral Treatment Effect as a Predictor
of the Development of Urethral Disintegration by Postoperative Day 14
Visualized treatment effect Sensitivity Specificity PPV NPV Accuracy
‡ Grade 1 1.00 0.30 0.75 1.00 0.77
‡ Grade 2 0.95 0.80 0.91 0.89 0.90
‡ Grade 3 0.38 1.00 1.00 0.45 0.58
PPV = photoselective vaporization of the prostate; NPV = negative predictive value.
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histotripsy treatment effect from normal urethra to disinte-
gration of the prostatic urethra. We then used these findings to
develop a grading scale to characterize the endoscopic ap-
pearance of the urethral treatment effect. While only 8.6% of
histotripsy treatments resulted in acute urethral disintegra-
tion, nearly 70% of treated zones ultimately exhibited urethral
disintegration within 2 weeks of treatment, indicating that
acute urethral fragmentation is not a reliable measure of ure-
thral damage. Such observations indicate an opportunity to
optimize effective treatment of the prostatic urethra to ensure
adequate tissue debulking and creation of a TURP-like defect.
Although histotripsy allows for noninvasive transcutane-
ous treatment of the canine prostate,12–14 this study specifi-
cally assessed the utility of postprocedure endoscopy as a
strategy to guide treatment of the prostatic urethra. The
finding of urothelial shedding (grade 2) on immediate post-
procedure cystoscopy was associated with a greater than 90%
success rate (PPV 0.91) of development of urethral disinte-
gration within 2 weeks of treatment. Further, producing a flap
of urothelium (grade 3) postprocedure was associated with
the development of frank urethral disintegration within 24 hrs
of the procedure in nearly 90% of cases. Such findings indicate
that cystoscopy could play a role in treating to a desired
amount of acute urethral damage to achieve subacute or
chronic urethral disintegration.
The observation of debris within treatment cavities adja-
cent to intact urethra suggests that urethral disintegration
may be needed for rapid drainage of homogenized adenoma
and effective tissue debulking for creation of a TURP-like
defect. The significance of undrained cavities remains to be
determined, however, including the chronicity of their evo-
lution and if cavity drainage is necessary for prostate histo-
tripsy treatment success.
While direct tissue fractionation from cavitation is clearly of
importance to the mechanism of action of histotripsy,8–10 our
data imply that there may be additional treatment effects that
contribute to the development of urethral disintegration.
Specifically, the observation that urethral disintegration de-
velops in 66% (21/32) of treatment zones chronically within 2
weeks in subjects without acute evidence of disintegration has
led us to hypothesize that there may be a component of tissue
ischemia contributing to urethral disintegration. This hy-
pothesis is supported by the observed progression of treat-
ment effect from the formation of petechial hemorrhage and
active bleeding to relative hemostasis and the appearance of
pale, gray, shaggy urothelium.
Initially, histotripsy damage may disrupt capillaries and
small vessels, leading to bleeding and hemorrhage. As damage
increases, vascular structures may be completely destroyed,
causing hemostasis, while other urethral structures begin to
show damage, such as shedding of the urothelium. Resulting
ischemia leads to breakdown and disintegration of the par-
tially fragmented portions of the urethra in the periprocedure
period, allowing drainage of the periurethral cavity. Such a
progression, could potentially account for the improved pos-
itive predictive value of grade 2 damage (pale, potentially
ischemic urothelium) compared with grade 1 damage
(potentially viable, bleeding urothelium) at predicting the
evolution of urethral disintegration in the chronic setting. Fi-
nally, a role for capillary/vascular damage in the effectiveness
of prostate histotripsy would also provide an explanation for
the reason prostate histotripsy is associated with minimal
hematuria, even in the setting of anticoagulation.14 Further
studies are ongoing to address this hypothesis.
Optimal prostate histotripsy treatment strategy remains to
be determined, and the generalizability of these results from
canine to human prostate is uncertain. Structurally, the canine
prostate is bilobed without zonal structures, whereas the
human prostate is subdivided into several different zones,
with potentially different treatment thresholds, with the
transition zone being most relevant to BPH. The vascular
anatomy of the prostate, however, is very similar between the
two species, with arterial branches from the internal pudendal
artery perforating the capsule to supply the stroma and
glandular tissues with the venous drainage in close proximi-
ty.15 In addition, the intraperitoneal location of the canine
prostate lends itself to a transabdominal histotripsy approach,
whereas structural modeling suggests that the human pros-
tate will likely be more amenable to a transperineal ap-
proach16 or transrectal approach. Ultimately, human studies
are needed to determine both the clinical efficacy and optimal
treatment algorithm for prostate histotripsy.
Conclusion
In a canine model, prostate histotripsy targeting the urethra
results first in hemorrhage, followed by hemostasis and
shedding of the urothelium, subsequent urothelial flap crea-
tion, and finally urethral disintegration. Acute urethral frag-
mentation after histotripsy of the prostate is not necessary to
achieve urethral disintegration in the chronic setting, how-
ever. Treating until endoscopic evidence of urothelial shed-
ding is present (grade 2 treatment effect) may be a strategy
(PPV 0.91) to achieve reliable urethral disintegration. Further
studies are needed to determine if urethral disintegration is
necessary for maximal treatment benefit and how reliably
these findings transfer to the human prostate.
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TURP¼ transurethral resection of the prostate
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